Revolution Medicines, Inc. (RVMD) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $144.49: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10 and A.R:R 1.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum.
Revolution Medicines is a clinical-stage precision oncology company developing RAS(ON) inhibitors. Lead asset daraxonrasib is in multiple Phase 3 trials for pancreatic cancer and NSCLC, with a key readout from RASolute 302 expected in H1 2026. The pipeline also includes... Read more
Sell if holding. Engine safety override at $144.49: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10 and A.R:R 1.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum. Chart setup: RSI 50 mid-range, Bollinger mid-band. Score 4.4/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.60, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Revolution Medicines, Inc.
Latest news
- GraniteShares Files High-Octane 2X ETFs Tied To Nuclear, AI, Biotech Momentum Stocks — benzinga May 19, 2026 positive
- Truist Securities Assumes Revolution Medicines at Buy, Raises Price Target to $179 — benzinga May 18, 2026 positive
- Stanley Druckenmiller Dumps Amazon And Alphabet While Loading Up On Commodities, Argentina And Biotech — benzinga May 18, 2026 neutral
- Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report — benzinga May 15, 2026 positive
- $100 Invested In Revolution Medicines 5 Years Ago Would Be Worth This Much Today — benzinga May 11, 2026 neutral
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinedaraxonrasib (RASolute 302)10-K Item 1: 'RASolute 302: comparing daraxonrasib against chemotherapy in patients with second line (2L) PDAC; a clinical readout for this study is currently expected in the first half of 2026'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $144.49: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10 and A.R:R 1.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum. Chart setup: RSI 50 mid-range, Bollinger mid-band. Prior stop was $134.26. Score 4.4/10, moderate confidence.
Take-profit target: $166.00 (+15.0% upside). Prior stop was $134.26. Stop-loss: $134.26.
Concentration risk — Pipeline: daraxonrasib (RASolute 302); Quality below floor (1.7 < 4.0).
Revolution Medicines, Inc. trades at a P/E of N/A (forward -25.4). TrendMatrix value score: 6.0/10. Verdict: Sell.
27 analysts cover RVMD with a consensus score of 4.4/5. Average price target: $184.
What does Revolution Medicines, Inc. do?Revolution Medicines is a clinical-stage precision oncology company developing RAS(ON) inhibitors. Lead asset...
Revolution Medicines is a clinical-stage precision oncology company developing RAS(ON) inhibitors. Lead asset daraxonrasib is in multiple Phase 3 trials for pancreatic cancer and NSCLC, with a key readout from RASolute 302 expected in H1 2026. The pipeline also includes zoldonrasib (G12D), elironrasib (G12C), and RMC-5127 (G12V).